Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplivanserin 5 mg/day for sleep maintenance insomnia
2005-003080-23Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Sleep initiation and maintenance disorder comparing Eplivanserin 5 mg/day with Placebo (2 arms). Primary endpoints: Wake time after sleep onset (pr-WASO) at 6 weeks and Wake time after sleep onset (pr-WASO) at 12 weeks. Started Nov 2005; status: completed.
02
Drugs
eplivanserin
03
Conditions
Sleep initiation and maintenance disorder
Beyond the preview
Go deeper on 2005-003080-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003080-23.